TDMS Study 97006-02 Pathology Tables
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
FINAL#1 MICE
Facility: Battelle Northwest
Chemical CAS #: 108-10-1
Lock Date: 01/24/03
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 10 9 6 9
Natural Death 5 3 5 3
Accidently Killed 1
Survivors
Terminal Sacrifice 35 37 39 38
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (44) (34) (40)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Colon (48) (48) (49) (49)
Intestine Large, Rectum (47) (48) (48) (49)
Sarcoma, Metastatic, Skin 1 (2%)
Intestine Large, Cecum (46) (48) (47) (49)
Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Duodenum (47) (48) (47) (48)
Adenoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Jejunum (48) (47) (47) (48)
Carcinoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Ileum (48) (47) (47) (47)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 3 (6%) 4 (8%) 4 (8%) 11 (22%)
Hepatocellular Carcinoma, Multiple 3 (6%) 1 (2%) 2 (4%)
Hepatocellular Adenoma 11 (22%) 10 (20%) 12 (24%) 9 (18%)
Hepatocellular Adenoma, Multiple 2 (4%) 5 (10%) 8 (16%) 14 (28%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 5 (10%)
Mesentery (11) (11) (13) (8)
Hemangiosarcoma, Metastatic, Spleen 1 (8%)
Hemangiosarcoma, Metastatic, Uterus 1 (8%)
Page 2
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hepatocholangiocarcinoma, Metastatic, Liver 1 (9%)
Histiocytic Sarcoma 1 (13%)
Sarcoma, Metastatic, Skin 1 (9%)
Pancreas (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Salivary Glands (50) (50) (50) (50)
Carcinoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 3 (6%)
Stomach, Glandular (49) (50) (48) (49)
Tooth (1) (1)
Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangioma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Adrenal Medulla (50) (50) (49) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Benign 2 (4%) 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Carcinoma 1 (2%)
Parathyroid Gland (28) (33) (30) (36)
Adenoma 1 (3%)
Pituitary Gland (50) (49) (48) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 3
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Distalis, Adenoma 7 (14%) 9 (18%) 4 (8%) 6 (12%)
Pars Intermedia, Adenoma 2 (4%)
Thyroid Gland (50) (50) (49) (48)
C-Cell, Adenoma 1 (2%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2) (1)
Hemangiosarcoma, Metastatic, Spleen 1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (45) (42) (41) (42)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Ovary (49) (50) (48) (50)
Cystadenoma 2 (4%) 1 (2%) 3 (6%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Uterus (50) (50) (49) (50)
Carcinoma 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (6%)
Leiomyoma 1 (2%) 1 (2%) 1 (2%)
Polyp Stromal 3 (6%) 2 (4%) 2 (4%)
Polyp Stromal, Multiple 1 (2%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Hemangiosarcoma, Metastatic, Spleen 1 (2%) 1 (2%)
Histiocytic Sarcoma 3 (6%) 1 (2%) 1 (2%)
Lymph Node (7) (3) (9) (5)
Iliac, Histiocytic Sarcoma 1 (11%)
Lumbar, Hemangiosarcoma 1 (11%)
Lumbar, Histiocytic Sarcoma 1 (20%)
Page 4
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Pancreatic, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (14%)
Renal, Histiocytic Sarcoma 1 (14%)
Lymph Node, Bronchial (44) (41) (39) (37)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (5%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (3%)
Lymph Node, Mandibular (40) (42) (39) (38)
Histiocytic Sarcoma 1 (3%) 1 (3%)
Lymph Node, Mesenteric (50) (49) (49) (47)
Hemangiosarcoma, Metastatic, Uterus 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Lymph Node, Mediastinal (46) (40) (38) (41)
Carcinoma, Metastatic, Skin 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 1 (3%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Spleen (50) (50) (49) (50)
Hemangiosarcoma 1 (2%) 2 (4%) 2 (4%) 1 (2%)
Hemangiosarcoma, Metastatic, Uterus 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Thymus (49) (47) (46) (46)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (49) (50) (49)
Carcinoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Skin (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 2 (4%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma,
Metastatic, Spleen 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Liposarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 3 (6%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
Page 5
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Skeletal Muscle (1) (2) (3) (2)
Carcinoma, Metastatic, Skin 1 (33%)
Hemangiosarcoma, Metastatic, Spleen 1 (33%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) 1 (50%)
Histiocytic Sarcoma 1 (50%)
Sarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (49) (50)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 2 (4%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Skin 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Hemangiosarcoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 1 (2%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 1 (2%)
Histiocytic Sarcoma 3 (6%) 1 (2%) 2 (4%)
Nose (50) (50) (50) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pleura (1)
Carcinoma, Metastatic, Skin 1 (100%)
Trachea (50) (50) (49) (50)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (49) (48) (49) (50)
Histiocytic Sarcoma 1 (2%)
Harderian Gland (49) (49) (49) (50)
Adenoma 6 (12%) 4 (8%) 2 (4%) 3 (6%)
Carcinoma 1 (2%) 3 (6%) 2 (4%) 3 (6%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 3 (6%)
Urinary Bladder (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 1 (2%) 6 (12%)
Lymphoma Malignant 13 (26%) 5 (10%) 11 (22%) 13 (26%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 40 40 42
Total Primary Neoplasms 75 60 73 84
Total Animals with Benign Neoplasms 29 29 30 33
Total Benign Neoplasms 37 37 39 40
Total Animals with Malignant Neoplasms 30 22 28 31
Total Malignant Neoplasms 38 23 34 44
Total Animals with Metastatic Neoplasms 9 3 4 1
Total Metastatic Neoplasm 27 19 11 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 9 6 12 9
Natural Death 1 2 3 4
Survivors
Terminal Sacrifice 40 42 34 37
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (49) (48) (47) (47)
Intestine Small, Duodenum (49) (48) (45) (47)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Jejunum (49) (48) (47) (47)
Adenoma 1 (2%)
Intestine Small, Ileum (49) (48) (48) (47)
Carcinoma 1 (2%) 1 (2%)
Liver (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 10 (20%) 11 (22%) 8 (16%) 7 (14%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%) 2 (4%) 2 (4%)
Hepatocellular Adenoma 11 (22%) 14 (28%) 11 (22%) 19 (38%)
Hepatocellular Adenoma, Multiple 6 (12%) 11 (22%) 12 (24%) 15 (30%)
Hepatocholangiocarcinoma 5 (10%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Mesentery (9) (3) (3) (4)
Sarcoma, Metastatic, Salivary Glands 1 (25%)
Pancreas (49) (50) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (48) (50)
Sarcoma 1 (2%)
Page 9
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Stomach, Forestomach (50) (49) (49) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (49) (49) (49) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 2 (4%)
Sarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Sarcoma, Metastatic, Bone 1 (2%)
Capsule, Adenoma 2 (4%) 1 (2%) 1 (2%)
Adrenal Medulla (50) (50) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Ganglioneuroma 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (49) (50) (49) (50)
Adenoma 1 (2%) 1 (2%) 3 (6%)
Pituitary Gland (50) (47) (48) (49)
Astrocytoma Malignant, Metastatic, Brain 1 (2%)
Histiocytic Sarcoma 1 (2%)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (50) (49) (50) (50)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Prostate (50) (49) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Seminal Vesicle (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50) (49)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 1 (2%)
Lymph Node (1) (2)
Lymph Node, Bronchial (39) (35) (37) (39)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) 2 (6%)
Sarcoma, Metastatic, Bone 1 (3%)
Lymph Node, Mandibular (37) (36) (32) (34)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Sarcoma, Metastatic, Salivary Glands 1 (3%)
Lymph Node, Mesenteric (49) (48) (48) (48)
Sarcoma, Metastatic, Bone 1 (2%)
Lymph Node, Mediastinal (42) (38) (36) (38)
Hepatocholangiocarcinoma, Metastatic, Liver 3 (7%) 2 (5%)
Sarcoma, Metastatic, Bone 1 (2%)
Spleen (50) (50) (49) (49)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (42) (44) (44) (47)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (49) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma, Metastatic,
Bone 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Skeletal Muscle (3) (2)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (67%) 2 (100%)
Sarcoma, Metastatic, Bone 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 5 (10%) 1 (2%) 5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 1 (2%) 3 (6%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 5 (10%) 3 (6%) 5 (10%)
Hepatocholangiocarcinoma, Metastatic, Liver 3 (6%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Salivary Glands 1 (2%)
Nose (50) (50) (50) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 12
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Sarcoma, Metastatic, Bone 1 (2%)
Pleura (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (49) (48) (49) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Harderian Gland (50) (49) (50) (50)
Adenoma 5 (10%) 4 (8%) 5 (10%) 7 (14%)
Carcinoma 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Bone 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Ureter (1)
Transitional Epithelium, Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 1 (2%) 3 (6%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 97006-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC METHYL ISOBUTYL KETONE Date: 04/29/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 07:47:59
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 450 PPM 900 PPM 1800 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 41 36 45
Total Primary Neoplasms 69 63 52 79
Total Animals with Benign Neoplasms 27 32 29 37
Total Benign Neoplasms 36 39 32 53
Total Animals with Malignant Neoplasms 29 21 16 20
Total Malignant Neoplasms 33 24 20 26
Total Animals with Metastatic Neoplasms 12 8 4 7
Total Metastatic Neoplasm 46 19 5 12
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------